The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

While the outcomes to weight loss drugs can be positive, Consumer Reports (CR) warns there are important considerations—especially for older adults—before starting these treatments.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Last week, Eli Lilly, the maker of Zepbound, also cut prices for its starter dose to $349 per month. Larger doses will now cost $499 per month through the company’s self-pay program.

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...